Replies to post #173006 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Smart.

Kate Moore
Project Manager at NICE -- National Institute for Health and Care Excellence
Manchester, Greater Manchester, United Kingdom Hospital & Health Care
Current

Project Manager
NICE - National Institute for Health and Care Excellence
2011 – Present (7 years) Manchester, United Kingdom
NICE - National Institute for Health and Care Excellence

Administrator
NICE - National Institute for Health and Care Excellence
2007 – 2011 (4 years)

Administrator
Manchester City Council
2003 – 2007 (4 years)Manchester, United Kingdom

Education
The University of Manchester
The University of Manchester
Master of Science (MSc), Mathematics and Physics
1998 – 2002

[monentum2play]

Expected publication date: 24 April 2019
https://www.nice.org.uk/guidance/indevelopment/gid-ta10143

Project lead Kate Moore

Timeline
Key events during the development of the guidance:

Date Update
03 April 2018 - 01 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
16 August 2017 As you will be aware, the Department of Health has asked NICE to conduct an appraisal of DCVax-L for treating newly diagnosed glioblastoma Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-June 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-August 2018
26 January 2017 - 23 February 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral
Thanks for the info. When you see it in print smacks right in the face.